Deerfield Management Company, L.P. (Series C) Edgewise Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,078,509 shares of EWTX stock, worth $54.4 Million. This represents 1.37% of its overall portfolio holdings.
Number of Shares
2,078,509
Previous 1,781,006
16.7%
Holding current value
$54.4 Million
Previous $47.5 Million
16.75%
% of portfolio
1.37%
Previous 0.88%
Shares
4 transactions
Others Institutions Holding EWTX
# of Institutions
216Shares Held
98.4MCall Options Held
885KPut Options Held
232K-
Orbimed Advisors LLC San Diego, CA15MShares$393 Million10.86% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$233 Million3.85% of portfolio
-
Baker Bros. Advisors LP New York, NY6.16MShares$161 Million1.82% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$157 Million0.0% of portfolio
-
Novo Holdings Hellerup, G75MShares$131 Million10.85% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.65B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...